問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

未分科

List

25Cases

2018-01-01 - 2020-12-31

Phase III

An open label study to evaluate the immunogenicity and safety of a tetanus toxoid vaccine in volunteers, seven years of age and older

  • Condition/Disease

    tetanus

  • Test Drug

    Tetana-Tetanus toxoid vaccine

Participate Sites
2Sites

Terminated1Sites

2017-01-05 - 2019-12-31

Others

An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors

  • Condition/Disease

    Solid Tumors

  • Test Drug

    TECENTRIQ

Participate Sites
6Sites

Recruiting4Sites

Terminated1Sites

趙毅
Taipei Veterans General Hospital

陳仁熙
Linkou Chang Gung Medical Foundation

2016-08-01 - 2021-01-10

Phase III

A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-First)

  • Condition/Disease

    Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

  • Test Drug

    Quizartinib (AC220)

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

柯博伸
Taipei Veterans General Hospital

2018-03-20 - 2024-03-31

Phase III

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome

  • Condition/Disease

    Acute Coronary Syndrome

  • Test Drug

    CSL112

Participate Sites
11Sites

Recruiting7Sites

Terminated3Sites

賴文德
Kaohsiung Municipal Gangshan Hospital

未分科

2022-06-01 - 2024-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting4Sites

Recruiting8Sites

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

2019-11-30 - 2022-05-19

Phase III

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy

  • Condition/Disease

    Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis

  • Test Drug

    Momelotinib Tablets；Danazol Capsules

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2017-02-17 - 2020-12-17

Phase III

A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease

  • Condition/Disease

    Crohn’s Disease

  • Test Drug

    Filgotinib

Participate Sites
13Sites

Recruiting8Sites

Terminated3Sites

邱正堂
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

吳登強
Kaohsiung Municipal Gangshan Hospital

未分科

2017-02-17 - 2020-12-17

Phase III

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease

  • Condition/Disease

    Active Crohn’s Disease

  • Test Drug

    Filgotinib, 100 mg and 200 mg per tablet

Participate Sites
14Sites

Recruiting9Sites

Terminated3Sites

吳登強
Kaohsiung Municipal Gangshan Hospital

未分科

邱正堂
Linkou Chang Gung Medical Foundation

2014-10-01 - 2025-12-31

Phase III

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF PALBOCICLIB (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF PREVIOUSLY UNTREATED ASIAN POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) ADVANCED BREAST CANCER

  • Condition/Disease

    breast cancer

  • Test Drug

    Palbociclib

Participate Sites
9Sites

Terminated9Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB